Obalon Therapeutics, Inc, a vertically integrated medical device company, focuses on developing and commercializing medical devices to treat people who are obese and overweight. The company offers the Obalon balloon system designed to provide weight loss in obese patients. Obalon Therapeutics, Inc was founded in 2008 and is headquartered in Carlsbad, California.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Phone844-362-2566
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$9.10 million
Profitability
Miscellaneous
Employees100
Next Earnings Date11/1/2019 (Estimated)
OptionableOptionable
Obalon Therapeutics (NASDAQ:OBLN) Frequently Asked Questions
What is Obalon Therapeutics' stock symbol?
Obalon Therapeutics trades on the NASDAQ under the ticker symbol "OBLN."
When did Obalon Therapeutics' stock split? How did Obalon Therapeutics' stock split work?
Obalon Therapeutics's stock reverse split before market open on Thursday, July 25th 2019. The 1-10 reverse split was announced on Wednesday, July 24th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, July 24th 2019. An investor that had 100 shares of Obalon Therapeutics stock prior to the reverse split would have 10 shares after the split.
How were Obalon Therapeutics' earnings last quarter?
Obalon Therapeutics Inc (NASDAQ:OBLN) announced its earnings results on Wednesday, July, 24th. The company reported ($0.25) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.27) by $0.02. The business earned $0.39 million during the quarter, compared to analyst estimates of $1.82 million. Obalon Therapeutics had a negative return on equity of 253.79% and a negative net margin of 425.36%. View Obalon Therapeutics' Earnings History.
When is Obalon Therapeutics' next earnings date?
What price target have analysts set for OBLN?
4 brokers have issued twelve-month price objectives for Obalon Therapeutics' shares. Their predictions range from $10.00 to $30.00. On average, they anticipate Obalon Therapeutics' share price to reach $20.63 in the next twelve months. This suggests a possible upside of 1,045.8% from the stock's current price. View Analyst Price Targets for Obalon Therapeutics.
What is the consensus analysts' recommendation for Obalon Therapeutics?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Obalon Therapeutics in the last year. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Obalon Therapeutics.
What are Wall Street analysts saying about Obalon Therapeutics stock?
Here are some recent quotes from research analysts about Obalon Therapeutics stock:
- 1. According to Zacks Investment Research, "Obalon Therapeutics, Inc. is a medical device company. It focused on developing and commercializing medical devices to treat obese and overweight. The company's product consists of Obalon balloon system, the first swallowable, gas-filled intragastric balloon designed to provide progressive and sustained weight loss in obese patients. Obalon Therapeutics, Inc. is based in San Diego, California. " (10/9/2019)
- 2. Northland Securities analysts commented, "We worry that it is only a question of time…… the company commentary this morning was spent on transitioning to the new brick & mortar business model." (7/24/2019)
Has Obalon Therapeutics been receiving favorable news coverage?
News stories about OBLN stock have been trending negative on Friday, according to InfoTrie Sentiment. The research group scores the sentiment of news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Obalon Therapeutics earned a media sentiment score of -2.0 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Obalon Therapeutics.
Are investors shorting Obalon Therapeutics?
Obalon Therapeutics saw a drop in short interest in September. As of September 15th, there was short interest totalling 29,500 shares, a drop of 23.0% from the August 15th total of 38,300 shares. Based on an average trading volume of 531,000 shares, the short-interest ratio is currently 0.1 days. Currently, 0.7% of the company's shares are short sold. View Obalon Therapeutics' Current Options Chain.
Who are some of Obalon Therapeutics' key competitors?
Some companies that are related to Obalon Therapeutics include SANUWAVE Health (SNWV), Nuvectra (NVTR), Interpace Diagnostics Group (IDXG), PAVmed (PAVM), Arch Therapeutics (ARTH), Neovasc (NVCN), Co-Diagnostics (CODX), Biostage (BSTG), RA Medical Systems (RMED), Restoration Robotics (HAIR), Atossa Genetics (ATOS), Hancock Jaffe Laboratories (HJLI), Lianluo Smart (LLIT), Titan Medical (TMDI) and DarioHealth (DRIO).
What other stocks do shareholders of Obalon Therapeutics own?
Who are Obalon Therapeutics' key executives?
Obalon Therapeutics' management team includes the folowing people:
- Mr. Andrew P. Rasdal, Exec. Chairman (Age 61)
- Dr. Kelly Huang Ph.D., CEO, Pres & Director (Age 50)
- Mr. William John Plovanic CFA, CFO & Sec. (Age 50)
- Mr. Mark C. Brister, Chief Technology Officer (Age 57)
- Ms. Daina Schmidt, VP of Marketing
When did Obalon Therapeutics IPO?
(OBLN) raised $75 million in an initial public offering on Thursday, October 6th 2016. The company issued 5,000,000 shares at $14.00-$16.00 per share. UBS Investment Bank, Canaccord Genuity and Stifel acted as the underwriters for the IPO and BTIG was co-manager.
Who are Obalon Therapeutics' major shareholders?
Obalon Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Interwest Venture Management Co. (6.83%). Company insiders that own Obalon Therapeutics stock include Amy Vandenberg, Interwest Partners X Lp, Kim P Kamdar, Neil Drake, Nooshin Hussainy, Parters Vii L P Domain and William J Plovanic. View Institutional Ownership Trends for Obalon Therapeutics.
Which institutional investors are selling Obalon Therapeutics stock?
How do I buy shares of Obalon Therapeutics?
Shares of OBLN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Obalon Therapeutics' stock price today?
One share of OBLN stock can currently be purchased for approximately $1.80.
How big of a company is Obalon Therapeutics?
Obalon Therapeutics has a market capitalization of $10.03 million and generates $9.10 million in revenue each year. The company earns $-37,380,000.00 in net income (profit) each year or ($19.60) on an earnings per share basis. Obalon Therapeutics employs 100 workers across the globe.View Additional Information About Obalon Therapeutics.
What is Obalon Therapeutics' official website?
How can I contact Obalon Therapeutics?
Obalon Therapeutics' mailing address is 5421 Avenida Encinas Suite F, Carlsbad CA, 92008. The company can be reached via phone at 844-362-2566 or via email at [email protected]
MarketBeat Community Rating for Obalon Therapeutics (NASDAQ OBLN)
MarketBeat's community ratings are surveys of what our community members think about Obalon Therapeutics and other stocks. Vote "Outperform" if you believe OBLN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OBLN will underperform the S&P 500 over the long term. You may vote once every thirty days.
